NCT01802749

Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer

Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 406 (actual)
• Sponsor: National Cancer Institute, Naples · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Bevacizumab has been found to prolong progression free survival in first line, and more recently, in second line treatment for platinum sensitive ovarian cancer patients who had not received prior treatment with bevacizumab. Recently reported data suggest that patients with colon cancer who receive bevacizumab in more than one line of therapy (beyond progression) have better results. In ovarian cancer, the role of bevacizumab administered in both first and second-line therapies needs to be defined. This study aims to evaluate whether administering bevacizumab in combination with chemotherapy in second-line therapy to patients with recurrent ovarian cancer who have received first-line bevacizumab will be more effective than chemotherapy alone.

Conditions

• Recurrent Ovarian Cancer

Interventions

Type	Name	Description
DRUG	Bevacizumab
DRUG	Paclitaxel
DRUG	Carboplatin
DRUG	pegylated liposomal doxorubicin
DRUG	Gemcitabine

Timeline

• Start date: 2013-11-01
• Primary completion: 2023-12-01
• Completion: 2023-12-01
• First posted: 2013-03-01
• Last updated: 2023-03-24

Locations

82 sites across 5 countries: France, Greece, Italy, Monaco, Switzerland